Randomised controlled trial of clinical medication review by a

pharmacist of elderly patients receiving repeat prescriptions in general practice by Zermansky, A.G et al.
Primary care
Randomised controlled trial of clinical medication review
by a pharmacist of elderly patients receiving repeat
prescriptions in general practice
Arnold G Zermansky, Duncan R Petty, David K Raynor, Nick Freemantle, Andy Vail, Catherine J Lowe
Abstract
Objective To determine whether a pharmacist can
effectively review repeat prescriptions through
consultations with elderly patients in general practice.
Design Randomised controlled trial of clinical
medication review by a pharmacist against normal
general practice review.
Setting Four general practices.
Participants 1188 patients aged 65 or over who were
receiving at least one repeat prescription and living in
the community.
Intervention Patients were invited to a consultation at
which the pharmacist reviewed their medical
conditions and current treatment.
Main outcome measures Number of changes to
repeat prescriptions over one year, drug costs, and use
of healthcare services.
Results 590 (97%) patients in the intervention group
were reviewed compared with 233 (44%) in the
control group. Patients seen by the pharmacist were
more likely to have changes made to their repeat
prescriptions (mean number of changes per patient
2.2 v 1.9; difference = 0.31, 95% confidence interval
0.06 to 0.57; P = 0.02). Monthly drug costs rose in
both groups over the year, but the rise was less in the
intervention group (mean difference £4.72 per 28
days, − £7.04 to − £2.41); equivalent to £61 per
patient a year. Intervention patients had a smaller rise
in the number of drugs prescribed (0.2 v 0.4; mean
difference − 0.2, − 0.4 to − 0.1). There was no
evidence that review of treatment by the pharmacist
affected practice consultation rates, outpatient
consultations, hospital admissions, or death rate.
Conclusions A clinical pharmacist can conduct
effective consultations with elderly patients in general
practice to review their drugs. Such review results in
significant changes in patients’ drugs and saves more
than the cost of the intervention without affecting the
workload of general practitioners.
Introduction
Over 80% of drugs prescribed by general practitioners
in the United Kingdom are repeat prescriptions—that
is, they are represcribed without a consultation
between the doctor and the patient.1 Repeat prescrib›
ing is poorly managed in the United Kingdom.2 In
1994, the Audit Commission suggested that the review
of long term treatment might be inadequate.3 Zerman›
sky subsequently found that 72% of repeat prescrip›
tions sampled in 50 practices had not been reviewed in
the past 15 months.2 He concluded that this is
potentially both wasteful and dangerous. Purves and
Kennedy expressed concern about the variation in the
quality of review between practices.4
The Royal College of Physicians and the recent
National Service Framework for Older People empha›
sise the need for regular review of treatment for elderly
patients.5 6 In view of the increasing workload of
general practitioners, it has been proposed that
pharmacists should review patients. Several North
American trials have shown the benefits of pharmacists
reviewing long term prescriptions in community
practice.7–11 In the United Kingdom, two limited
randomised controlled trials suggest that review of
treatment by pharmacists identifies more drug related
problems than normal care.12 13 We tested whether
pharmacists can effectively review the conditions and
treatments of elderly patients in consultation with the
patient.
Participants and methods
Design
The study was a stratified randomised controlled trial
and was approved by local research ethics committees.
We calculated the sample size on the secondary
outcome measure of cost of repeat drugs. This was
because we expected the primary outcome, number of
changes over 12 months, to show larger differences.
The predicted difference in costs was £24 per patient a
year, based on a previous study.14 We needed a sample
size of 600 per group to give 80% power to detect a
cost difference at the 5% significance level with a possi›
ble 15% loss to follow up.
Selection criteria and randomisation
We recruited general practices by randomly selecting
them from a list of all practices in Leeds Health
Authority with four or more partners, computerised
repeat prescribing, no previous or current clinical
pharmacist involvement, and prescribing costs close to
average. We approached practices in random order
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until four had been recruited. One declined to partici›
pate, and we rejected another that was changing its
computer system.
The participating practices provided complete lists
of registered patients aged 65 and over who were
receiving at least one drug on repeat prescription on 1
June 1999. We excluded patients in nursing or residen›
tial homes, those who had a terminal illness, and those
who were in clinical trials. We wrote to eligible patients
asking them to participate. Those who consented were
randomised to an intervention group (clinical review
by pharmacist) or control group (normal care) by
computer generated random numbers. Randomisation
was stratified by general practice (four levels), age
(65›74 years v >75 years), and number of drugs (<4 v
>5).
Intervention
The pharmacist (DRP) invited patients to his clinic
when their next review was due. Patients with no review
date were invited to attend when convenient. Immobile
patients were visited at home. Non›attenders were
invited once more by telephone.
The intervention has been described previously
and is summarised as an algorithm (fig 1).15 During the
consultation with the patient, the pharmacist discussed
each condition being treated and asked about relevant
symptoms (such as swollen ankles and breathlessness
in patients with heart failure). In conditions for which
clinical or pathological monitoring was due, the phar›
macist directed the patient to the practice nurse or
doctor. The pharmacist did not physically examine the
patient, although he noted signs that were obvious
during the consultation, such as swollen ankles or rash.
Patients with new clinical problems were referred to
the doctor.
Treatment recommendations were based on
national, local, and (where available) practice guide›
lines. We agreed with each practice the level of
intervention that the pharmacist could make without
seeking prior approval.
Usual care
Patients in the control group continued to receive nor›
mal care from their general practitioner and primary
healthcare staff. Patients were recalled for review of
treatment by the general practitioner according to
normal custom in the practice.
Outcome measures
The primary outcome measure was the number of
changes to repeat prescriptions between baseline (June
1999) and the end of the 12 month study (June 2000).
The secondary outcome measures were changes in
number and cost of medicines and frequency of dose
and effect on healthcare workload (general practitioner
consultations, hospital outpatient attendances, and
acute admissions).
Collection of data
As well as the age and sex of patients, we recorded
number of repeat prescriptions, number of times doses
were taken a day, and net ingredient cost of 28 days’
supply (based on Drug Tariff and Monthly Index of
Medical Specialties for December 1998) at baseline and
the end of the study. The number of consultations
within the practice, outpatient attendances, and acute
admissions were recorded for the duration of the study.
We recorded drop out due to death, leaving the
practice, or going into a residential home. We also col›
lected data for six months before the intervention to
allow us to test whether the pharmacist’s presence con›
taminated the control group.
Statistical analysis
Analysis was by intention to treat.16 We compared pre›
scribing rates using standard two group comparisons.
Regression analyses that adjusted for stratification fac›
tors did not qualitatively affect the conclusions and are
not reported.
Results
The four practices had a total list size of 28 202
(individual sizes 6342, 7647, 8759, and 5454) with 3308
patients aged 65 and over. In all, 2505 patients met our
inclusion criteria, but 33 were excluded at their
doctors’ request. We contacted 2403 patients consecu›
tively until the required number of participants was
Clinical medication review
Clinical medication review is the process where a
health professional reviews the patient, the illness, and
the drug treatment during a consultation. It involves
evaluating the therapeutic efficacy of each drug and
the progress of the conditions being treated. Other
issues, such as compliance, actual and potential
adverse effects, interactions, and the patient’s
understanding of the condition and its treatment are
considered when appropriate. The outcome of the
review will be a decision about the continuation (or
otherwise) of the treatment.
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Fig 1 Process for reviewing repeat prescriptions
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obtained;1188 consented. Figure 2 shows the progress
of participants through the trial. There was even distri›
bution of age, sex, practice, and number of drugs on
repeat prescription between the intervention and con›
trol groups (table 1), and there were no differences in
drug costs or number of doses (table 2) at baseline.
Records on drugs were unavailable for 11 cases: seven
had died (six in the intervention group) and four (all
intervention group) had left the practices in the inter›
val between consent and examining the records.
Outcomes
By June 2000, 40 (3%) patients had died (15 interven›
tion and 25 control group) and 17 (1%) had left the list
(12 intervention and five control group). Records were
unavailable for a further two patients (both interven›
tion group), leaving 1131 patients with adequate data
for inclusion in the principal analyses.
The mean number of changes per patient was 2.2
in the intervention group and 1.9 in the control group
(difference = 0.31, 95% confidence interval 0.06 to
0.57; P = 0.02). Table 3 shows the numbers of patients
who had at least one change to their treatment during
the study. More patients in the control group than the
intervention group started taking a new drug. There
was no clear difference in the number of other
changes.
Table 4 shows the differences between baseline and
follow up in the numbers, costs, and doses of repeat
prescriptions. Numbers of drugs and cost rose in both
groups, but for each the rise was significantly less in the
intervention group. The number of daily doses did not
differ significantly. There was no evidence of any
adverse health outcome in the intervention group as
measured by need for consultation with a general
practitioner or hospital treatment (table 5). The
number of deaths was 15 (2.5%) in the intervention
group and 25 (4.3%) in the control group (odds
ratio = 0.56, 0.29 to 1.1).
In all, 590 (97%) intervention patients had a
consultation with the pharmacist (one was seen twice).
Of the 18 who were not seen, eight had died, four had
moved, three declined, and three were not receiving
repeat prescriptions. In the control group, 233 (44%)
patients had a documented review with a doctor.
The pharmacist took an average of 20 minutes to
conduct a review (excluding collection of research
data). The gross cost of the pharmacist was £21 per
Practice population >65 years (n=3308)
Met criteria (n=2505)
Invited to participate (n=2403)
Consented (n=1188)
Intervention (n=608) Control (n=580)
Available for analysis (n=581) Available for analysis (n=550)
Not on repeat drugs (n=701)
In nursing or residential
  homes (n=69)
Excluded at request of general
  practitioner (n=33)
Declined to participate or
  not contactable (n=1215)
Lost before intervention (n=10):
Died (n=6)
Left list (n=4)
Died before baseline
data collection (n=1)
Lost after intervention (n=17):
Died (n=9)
Left list (n=8)
Lost after baseline
data collection (n=29):
Died (n=24)
Left list (n=5)
Fig 2 Randomisation of patients and reasons for exclusion from
final analysis
Table 1 Stratification factors and demographic data for
intervention and control groups at baseline
Intervention* Control
No from each practice:
A 147 124
B 182 175
C 148 144
D 131 137
Total 608 580
Mean (SD age) 74 (6.6) 73 (6.4)
No (%) of women 339 (56) 325 (56)
No (interquartile range) of repeated drugs 4 (2›7) 4 (2›6)
*Four patients were subsequently found not to be receiving a repeat prescription.
Table 2 Median (interquartile range) cost and dosage of repeat
prescriptions at start of trial
Factor
Intervention
n=598
Control
n=579
Total
n=1177
Repeats cost (£/month) 20 (7›38) 21 (7›39) 20 (7›39)
No of dose times/day 2 (1›3) 2 (1›3) 2 (1›3)
Table 3 Numbers (percentages) of patients whose repeat
prescriptions were changed during the study. Some patients had
more than one change
Type of change
Intervention
(n=581)
Control
(n=550)
Total
(n=1131)
New drug started 265 (46) 270 (49) 535 (47)
Drug stopped 239 (41) 180 (33) 419 (37)
Switched drug 119 (20) 93 (17) 212 (19)
Dose changed 98 (17) 61 (11) 159 (14)
Change to generic 64 (11) 37 (7) 101 (9)
Formulation changed 17 (3) 12 (2) 29 (3)
Frequency changed 6 (1) 0 6 (1)
Any of above 438 (75) 397 (72) 835 (74)
Table 4 Changes in treatment between the start and finish of study
Intervention Control
Difference between
groups (95%CI) P value*
Start
(n=596)
Finish
(n=576) Change
Start
(n=577)
Finish
(n=549) Change
Mean No of repeat medicines 4.8 5.0 0.2 4.6 5.0 0.4 −0.2 (−0.4 to−0.1) 0.01
Mean cost over 28 days (£) 29.27 31.07 1.80 28.23 34.85 6.52 −4.72 (−7.04 to −2.41) 0.0001
Mean No of dose times/day 2 1.9 −0.1 2.1 1.9 −0.2 0.1 (0.0 to 0.2) 0.17
*t test.
Primary care
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hour, or £7 per patient reviewed. The average
reduction in net cost of drugs per patient per 28 days
was £4.72 (£2.41 to £7.04).
Discussion
We have shown that a trained pharmacist can conduct
clinical medication reviews of elderly patients in the
general practice setting. The pharmacist’s review
resulted in more changes to treatment than normal
care and produced an important cost saving, even after
the cost of the intervention was deducted.
Validity
We recruited half of contacted patients. There was con›
cern that the participants might not be typical of the
practices’ eligible elderly populations. We have shown
previously that the participants tended to be younger,
male, and taking fewer drugs than non›participants.17
This suggests that our results may underestimate the
effects of the review. Patients taking more drugs are
more likely to benefit from the pharmacist’s interven›
tion, provided that they can be persuaded to attend a
review. Attendance would be more likely in the context
of care rather than a clinical trial.
The unit of randomisation was the patient. Thus
practices contained both intervention and control
patients. We collected data for the six months before
the study started in response to concern that contami›
nation could occur as a result of the pharmacist’s pres›
ence in the practice. Comparison of these data with
study data showed no evidence of contamination.
Reasons for difference between groups
The smaller increase in the mean number of repeat
prescriptions in the intervention group was mainly due
to these patients being more likely to have drugs
stopped. Intervention patients had more changes to
treatment in general, perhaps because the pharmacist
did a more detailed review than the general practition›
ers. This effect could be important because patients’
compliance has been shown to decrease with
increasing number of drugs.18 Stopping unnecessary
drugs may also reduce the risk of adverse effects and
interactions.
Review of drug treatment by pharmacists could
have increased general practice consultation rates if
patients made appointments to confirm advice given
by the pharmacist, to have tests done, or to have treat›
ment recommendations implemented. Consultations
did increase immediately after the review, but the total
number in the year was not different from that in the
control group. The increase in consultations was due to
patients requiring tests (usually referred to the practice
nurse) or to suspected worsening of an existing condi›
tion or a new condition (referral to the general
practitioner). The extra workload was therefore appro›
priate and was balanced by a reduced workload in the
subsequent months.
A potentially interesting outcome was the smaller
number of deaths in the intervention group. We did
not specify deaths as a secondary outcome, and the
study was not powered to detect a difference in
mortality. The non›significant difference may be due to
the play of chance or to patients stopping inappropri›
ate and harmful medicines, or perhaps because
patients who had lost contact with their doctor were
returned to surveillance.
We adopted a clinical patient centred approach
rather than relying on technical appraisal of the drugs,
as in some other studies.12 19 This resulted in more
clinical interventions such as ensuring treatment was
monitored, identifying new health problems, suggest›
ing new interventions, and reinforcing compliance.
Our study supports the concept of medication review
suggested in the National Service Framework for
Older People.6
The small scale of this trial, involving only four
practices in one city and just one pharmacist, limits the
generalisability of the results. Nevertheless, it shows
that significant and clinically important results can be
achieved by pharmacists reviewing patients and their
treatment. A larger scale study with more practices and
pharmacists is needed to clarify the practicality, costs,
and benefits.
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Table 5 Use of health services for 12 months from June 1999
to May 2000. Values are median (interquartile range) unless
stated otherwise
Service
Intervention
(n=579)
Control
(n=550) P value
No of general practice consultations 6 (3›10) 6 (3›10) 0.69*
No of outpatient appointments 1 (03) 1 (0›3) 0.41*
No (%) admitted to hospital:
Never 469 (81) 458 (83)
Once 78 (13) 55 (10) 0.16†
More than once 32 (6) 37 (7)
*Mann›Whitney test.
†÷2 test.
What is already known on this topic
Review of patients on long term drug treatment is
important but is done inadequately
Evidence from the United States shows that
pharmacists can improve patient care by reviewing
drug treatment
What this study adds
Consultations with a clinical pharmacist are an
effective method of reviewing the drug treatment
of older patients
Review by a pharmacist results in more drug
changes and lower prescribing costs than normal
care plus a much higher review rate
Use of healthcare services by patients is not
increased
Primary care
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